Germ Cell Tumors – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Germ Cell Tumors – Drugs In Development, 2024 report and make more profitable business decisions.
Germ cell tumors (GCTs), originating from primordial germ cells, exhibit diverse neoplasms primarily in gonads but also in the anterior mediastinum, pineal gland, and brain. Clinical classification distinguishes seminomas and non-seminomas, each with distinct prognoses. Seminomas typically show favorable outcomes, while non-seminomatous tumors may present with metastasis, including mixed germ cell components. Diagnosing germinoma involves imaging, serum/cerebrospinal fluid oncoprotein measurements, and histological biopsy. Germinoma boasts a favorable prognosis with over 90% 5-year survival rates, highly responsive to radiotherapy (RT) and chemotherapy (CT). Current practices favor whole ventricular irradiation over craniospinal irradiation due to reduced side effects. Platinum-based CT combinations precede low-dose ventricular irradiation, minimizing toxicity. Surgical roles are limited, mainly for diagnosis and managing obstructive hydrocephalus, with second-look surgery considered for non-responsive tumors.
The Germ Cell Tumors drugs in development market research report provide comprehensive information on the therapeutics under development for Germ Cell Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Germ Cell Tumors and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Germ Cell Tumors | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Germ Cell Tumors therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Germ Cell Tumors pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Germ Cell Tumors treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AstraZeneca PlcBristol-Myers Squibb Co
Changzhou Qianhong Bio-Pharma Co Ltd
Daiichi Sankyo Co Ltd
GAiA BioMedicine Inc
Gan & Lee Pharmaceuticals Co Ltd
Kronos Bio Inc
Merck & Co Inc
Mereo Biopharma Group Plc
Novartis AG
Ohara Pharmaceutical Co Ltd
Pharma Mar SA
Sanofi
Treovir LLC
UNC Lineberger Comprehensive Cancer Center
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Germ Cell Tumors reports